| Name | Title | Contact Details |
|---|
Abington Memorial Hospital, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Abington Memorial Hospital, Inc. is based in Abington, PA. You can find more information on Abington Memorial Hospital, Inc. at www.amh.org
Stanford Hospital and Clinics is located on the northern end of the Stanford University campus in Palo Alto, California.
Vinfen Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The University of Maryland Medical System (UMMS) is a university-based regional health care system focused on serving the health care needs of Maryland. We bring innovation, discovery and research to the care we provide all while educating the state`s future physicians and health care professionals through our partnership with the University of Maryland School of Medicine and the UM Schools of Nursing, Pharmacy, Social Work and Dentistry in Baltimore. As one of the largest private employers in the state, the health system`s 25,000 employees and 4,000 affiliated physicians provide primary and specialty care in more than 150 locations and at 13 hospitals. UMMS` flagship academic campus, the University of Maryland Medical Center in Baltimore, is recognized regionally and nationally for excellence and innovation in specialized care. Our acute care and specialty rehabilitation hospitals serve urban, suburban and rural communities and are located in 13 counties across the state. In addition, UMMS operates health insurance plans serving Medicare and Medicaid members.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.